Adagio updates on ADG20 development plans and pipeline

22 February 2022

US biotech Adagio Therapeutics (Nasdaq: ADGI) today outlined strategic initiatives for its ADG20 program, as well as research efforts to address SARS-CoV-2 and other coronaviruses. ADG20 is an investigational monoclonal antibody (MAb) being developed for the prevention and treatment of COVID-19.

Adagio’s shares edged up 3.3% to $6.63 by mid-morning trading.

The persistence of the COVID-19 pandemic and the potential for new variants support Adagio’s ongoing work to bring forward new prevention and treatment options. Adagio is undertaking several strategic initiatives intended to assess the potential for Emergency Use Authorization submissions for ADG20 for the prevention and treatment of COVID-19, as well as numerous research efforts to address COVID-19 and other coronaviruses. In the first quarter of 2022, Adagio plans to:

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK